Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Malignant Neoplasms
|
1641 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.030 | 1.000 | 3 | 2017 | 2018 | |||||
Neoplasms
|
1644 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.030 | 1.000 | 3 | 2015 | 2017 | |||||
Primary malignant neoplasm
|
1374 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.030 | 1.000 | 3 | 2017 | 2018 | |||||
Breast Carcinoma
|
2793 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.020 | 1.000 | 2 | 2016 | 2017 | |||||
Carcinoma of lung
|
1204 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.020 | 0.500 | 2 | 2018 | 2018 | |||||
Malignant neoplasm of breast
|
3417 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.020 | 1.000 | 2 | 2016 | 2017 | |||||
Malignant neoplasm of lung
|
1142 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.020 | 0.500 | 2 | 2018 | 2018 | |||||
Malignant neoplasm of prostate
|
1082 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.020 | 0.500 | 2 | 2017 | 2018 | |||||
Primary malignant neoplasm of lung
|
981 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.020 | 0.500 | 2 | 2018 | 2018 | |||||
Prostate carcinoma
|
1168 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.020 | 0.500 | 2 | 2017 | 2018 | |||||
Autism Spectrum Disorders
|
331 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1.000 | 1 | 2020 | 2020 | |||||
Benign Prostatic Hyperplasia
|
91 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Carcinogenesis
|
355 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1 | 2017 | 2017 | ||||||
Central neuroblastoma
|
231 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Childhood Neuroblastoma
|
231 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Familial lichen amyloidosis
|
24 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Gastric Adenocarcinoma
|
235 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Giant Cell Arteritis
|
78 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Glioma
|
353 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1 | 2017 | 2017 | ||||||
Malignant neoplasm of stomach
|
615 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Neoplasm Metastasis
|
327 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Neuroblastoma
|
386 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Pervasive Development Disorder
|
49 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1.000 | 1 | 2020 | 2020 | |||||
Rheumatoid Arthritis
|
2387 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1 | 2017 | 2017 | ||||||
Stomach Carcinoma
|
652 | 0.683 | 0.480 | 12 | 53961717 | upstream gene variant | C/T | snv | 0.38 | 0.010 | 1.000 | 1 | 2017 | 2017 |